H.C. Wainwright lowered the firm’s price target on Jasper Therapeutics (JSPR) to $40 from $60 and keeps a Buy rating on the shares after the company announced initial data from the BEACON study evaluating briquilimab for treatment of chronic spontaneous urticaria. The firm says this morning’s stock selloff is overdone “as there was clear evidence of efficacy with briquilimab and tolerable safety.” While some investors were likely hoping for every 12 weeks dosing, the eight week dosing is still positive and longer-term data will be more informative of potential differentiation versus competitors, contends H.C. Wainwright. It believes briquilimab data bode well competitively and its notes that patient numbers are still small. Jasper in midday trading is down 56%, or $9.84, to $7.88.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JSPR:
- Jasper data alleviates competitive concerns for Celldex, says Citi
- Jasper Therapeutics reports data from BEACON study of briquilimab
- 3 Best Stocks to Buy Now, 1/3/2025, According to Top Analysts
- 3 Best Stocks to Buy Now, 12/24/2024, According to Top Analysts
- Jasper Therapeutics initiated with an Outperform at BMO Capital
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
